Drug Overview: Aranesp

  • ID: 4462214
  • Drug Pipelines
  • 32 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia. The drug targets the erythropoietin receptor, initiating the same pathway as native erythropoietin, and triggering increased blood production in bone marrow.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Aranesp: Anemia in chronic kidney disease
Aranesp: Chemotherapy-induced anemia

List of Figures
Figure 1: Aranesp for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of Aranesp for anemia in chronic kidney disease
Figure 3: Drug assessment summary of Aranesp for anemia in chronic kidney disease
Figure 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 5: Aranesp for chemotherapy-induced anemia - SWOT analysis
Figure 6: Drug assessment summary of Aranesp in chemotherapy-induced anemia
Figure 7: Drug assessment summary of Aranesp in chemotherapy-induced anemia

List of Tables
Table 1: Aranesp drug profile
Table 2: Aranesp pivotal trial data in anemia in chronic kidney disease
Table 3: Aranesp other late-phase trial data in anemia in chronic kidney disease
Table 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 5: Aranesp drug profile
Table 6: Aranesp pivotal trial data in chemotherapy-induced anemia
Table 7: Aranesp late-phase trial data in chemotherapy-induced anemia
Table 8: Aranesp ongoing late-phase clinical trial in chemotherapy-induced anemia
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll